ASCO 2018 Multiple Myeloma Abstracts –
Poster Presentations
Poster presentations related to multiple myeloma will take place primarily the morning of Monday, June 4, at the 2018 American Society of Clinical Oncology (ASCO) annual meeting.
The list below contains the titles and authors of all multiple myeloma poster presentations at ASCO 2018. Each entry in the list also includes a link to the full text of the relevant abstract at the ASCO website.
Links to PDF files containing posters will be added to entries in this list as those files are made available to The Beacon courtesy of the ASCO presenters.
The Beacon also has complete lists of all ASCO 2018 multiple myeloma-related oral presentations, education session presentations, and e-abstracts, as well as news articles about multiple myeloma at the ASCO 2018 meeting.
| Session | Health Services Research, Clinical Informatics, and Quality of Care |
| Type | Poster Session |
| Time | Saturday, June 2, 1:15 PM - 4:45 PM |
| Location | Hall A |
6580 - Toward understanding toxicity over time (ToxT) in myeloma cooperative group trials: Feasibility of a novel longitudinal adverse event analysis in ECOG-ACRIN E1A06
Susanna J. Jacobus, Paul J. Novotny, A. Keith Stewart, Rahma M. Warsame, Natalie Scott Callander, Rafael Fonseca, Madhu V. Midathada, Avina A. Singh, Timothy E. O'Brien, Donald MacFarlene, David L. Grinblatt, Asher Alban Akmal Chanan-Khan, S.Vincent Rajkumar, Amylou C. Dueck, Gita Thanarajasingam (abstract)
6585- Prediction of venous thromboembolism (VTE) in multiple myeloma (MM): Myeloma clot score (MCS)
Kristen Marie Sanfilippo, Tzu-Fei Wang, Suhong Luo, Kenneth Robert Carson, Theodore Seth Thomas, Brian Gage (abstract)
| Session | Hematologic Malignancies - Plasma Cell Dyscrasia |
| Type | Poster Session |
| Time | Monday June 4, 8:00 AM to 11:30 AM |
| Location | Hall A |
8009 - Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial)
Francesca Maria Gay, Robin Foà, Pellegrino Musto, Chiara Cerrato, Barbara Gamberi, Elena Zamagni, Angelo D. Palmas, Antonio Spadano, Paola Omedè, Tommaso Caravita, Nicola Giuliani, Stelvio Ballanti, Francesca Patriarca, Rossella Troia, Massimo Gentile, Giovanni Desabbata, Letizia Canepa, Antonio Palumbo, Michele Cavo, Mario Boccadoro (abstract)
8010 - A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185
Saad Zafar Usmani, Fredrik Schjesvold, Albert Oriol Rocafiguera, Lionel Karlin, Robert M. Rifkin, Habte Aragaw Yimer, Richard LeBlanc, Naoki Takezako, Robert Donald McCroskey, Kenshi Suzuki, Michele Cavo, Thierry Facon, Sundar Jagannath, Sagar Lonial, Razi Ghori, Mohammed Z.H. Farooqui, Jason Liao, Patricia Marinello, Jesus San-Miguel (abstract)
8012 - A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
Andrew Jenho Yee, Jacob Laubach, Erica Leigh Campagnaro, Brea Lipe, Omar Nadeem, Craig Cole, Elizabeth O'Donnell, Robert L. Schlossman, Giada Bianchi, Andrew Robert Branagan, Samantha J. Shapiro, Cynthia C. Harrington, Jill N. Burke, Marilyn T. Gammon, Kathleen J. Lively, Cassandra Ann Thorburn, Mason L. Mann, Jens Guenter Lohr, Paul G. Richardson, Noopur S. Raje (abstract, poster [PDF] courtesy of Dr. Yee)
8013 - Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO)
Ajai Chari, Saad Zafar Usmani, Maria-Victoria Mateos, Niels Van De Donk, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol Rocafiguera, Torben Plesner, Lotfi Benboubker, Kevin Liu, Peter Hellemans, Tara J. Masterson, Pamela L. Clemens, Andrew Farnsworth, Hareth Nahi, Jesus San-Miguel (abstract)
8014 - Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM)
Ajai Chari, Joshua Ryan Richter, Nina Shah, Sandy Wai Kuan Wong, Sundar Jagannath, Hearn J. Cho, Noa Biran, Jeffrey Wolf, Samir S. Parekh, Pamela N. Munster, Deepu Madduri, Frank Campana, Thomas G. Martin (abstract)
8015 - Low vs high dose carfilzomib (Cfz) with dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Results of SWOG S1304
Sikander Ailawadhi, Rachael Sexton, Suzanne Lentzsch, Muneer Hyder Abidi, Peter Michael Voorhees, Adam D. Cohen, Eric Rohren, Stephen Heitner, Kevin Kelly, Niklas J. Mackler, David M. Baer, Antje Hoering, Brian G. Durie, Robert Z. Orlowski (abstract)
8016 - Maintenance therapy (MT) with 25 versus 5 mg lenalidomide (Len) after prolonged Len consolidation therapy (CT) in newly-diagnosed, transplant-eligible patients (pts) with multiple myeloma (MM)
Roland Fenk, MD (abstract)
8017 - Carfilzomib weekly 20/56mg/m², lenalidomide and dexamethasone for early relapsed refractory multiple myeloma
Valentine Richez, Stephanie Guidez, Isabelle Azais, Geraldine Durand, Vincent Javaugue, Antoine Brigaud, Antoine Machet, Niels Moya, Cecile Gruchet, Arthur Bobin, Anthony Levy, Florence Sabirou, Celine Dieval, Emmanuel Fleck, Isabelle Princet, Delphine Bauwens, Guillemette Fouquet, Frank Bridoux, Herve Avet-Loiseau, Xavier Leleu (abstract)
8018 - Overall survival (OS) results of randomized phase III study (ADMYRE trial) of plitidepsin and dexamethasone (DXM) vs. DXM alone in patients with relapsed/refractory multiple myeloma (RRMM): Evaluation of the crossover impact
Javier Gomez, Sonia Extremera, Antonio Nieto (abstract)
8019 - Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial
Martin Gramatzki, Andreas Guenther, Massimo Offidani, Monika Martha Engelhardt, Vittorio Montefusco, Francesca Patriarca, Emanuele Angelucci, Marco Salvini, Wolfram Pönisch, Stefano Spada, Silvia Gentili, Ralph Wäsch, Natalie Schub, Paolo Corradini, Hermann Einsele, Pieter Sonneveld, Mario Boccadoro, Francesca Maria Gay (abstract)
8020 - Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma
Yarong Liu, Zhi Chen, Runhong Wei, Lin Shi, Feng He, Zixiao Shi, Tao Jin, Ronglin Xie, Baofeng Wei, Jing Chen, Hongliang Fang, Bo Zhu, Qi-Jing Li, Pin Wang (abstract)
8021 - A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183
Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol Rocafiguera, David Simpson, Anupkumar George, Hartmut Goldschmidt, Alessandra Larocca, Daniel Wayne Sherbenou, Irit Avivi, Shinsuke Iida, Morio Matsumoto, Saad Zafar Usmani, Sundar Jagannath, Paula Rodriguez-Otero, Uma Kher, Mohammed Z.H. Farooqui, Jason Liao, Patricia Marinello, Sagar Lonial (abstract)
8022 - Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study
Noa Biran, David Samuel DiCapua Siegel, Jesus G. Berdeja, Noopur S. Raje, Robert F. Cornell, Melissa Alsina, Tibor Kovacsovics, Belle Fang, Amy Kimball, Carl Ola Landgren (abstract)
8023 - Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma
Mohammed A. Aljama, M Hasib Sidiqi, Shaji Kumar, Taxiarchis Kourelis, Morie A. Gertz, S. Vincent Rajkumar, Wilson I. Gonsalves, Martha Lacy, Francis Buadi, Prashant Kapoor, Angela Dispenzieri, David Dingli, Nelson Leung, John Anthony Lust, Suzanne R. Hayman, Ronald S. Go, Lisa Hwa, Robert A. Kyle, Rahma M. Warsame (abstract)
8024 - Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma(RRMM) patients treated with bb2121 anti-BCMA CAR T cells
Nikhil C. Munshi, Jesus G. Berdeja, Yi Lin, James Kochenderfer, Noopur S. Raje, Michaela Liedtke, Sundar Jagannath, Deepu Madduri, Jacalyn Rosenblatt, Marcela Valderrama Maus, Ashley Turka, Lyh Ping Lam, Kristen Hege, Timothy Brandon Campbell, Monica Massaro, Fabio Petrocca, David Samuel DiCapua Siegel (abstract)
8025 - Autologous stem cell transplantation in multiple myeloma patients over age 75
Ning Dong, Phyllis McKiernan, David Samuel DiCapua Siegel, David H. Vesole, Scott D. Rowley, Tracy Andrews, Andrea Ortega, Alan P. Skarbnik, Noa Biran, Joshua Ryan Richter, Andrew Pecora, Andre Goy, Rima Panchal, Nino Aleksidze, Michele Donato (abstract)
8026 - Single cell analysis of multiple myeloma
Guy Ledergor, Assaf Weiner, Mor Zada, Yael Chava Cohen, Moshe E Gatt, Nimrod Snir, Hila Magen, Maya Koren-Michowitz, Hadas Keren-Shaul, Venkata Yellapantula, Bruno Paiva, Arnon Nagler, Jesus San-Miguel, Dina Ben-Yehuda, Elli Papaemmanuil, Irit Avivi, Gabriel I Barbash, Amos Tanay, Ido Amit (abstract)
8027 - Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure
David Samuel DiCapua Siegel, Gary J. Schiller, Christy Joy Samaras, Michael Sebag, Jesus G. Berdeja, Siddhartha Ganguly, Jeffrey Matous, Kevin W. Song, Christopher Seet, Giampaolo Talamo, Shanthi Srinivas, Mirelis Acosta-Rivera, Michael Bar, Donald Quick, Bertrand Marquess Anz, Gustavo Fonseca, Donna Ellen Reece, Faiza Zafar, Weiyuan Chung, Nizar J. Bahlis (abstract)
8028 - Graft-versus-host disease (GVHD) risk with daratumumab (Dara) therapy post allogeneic transplantation (alloHCT) for multiple myeloma (MM)
Liana Nikolaenko, Saurabh Chhabra, Parameswaran Hari, Amrita Y. Krishnan, Joshua Ryan Richter (abstract)
8029 - A phase 1/2 study of carfilzomib, bendamustine, and dexamethasone (CBD) in newly diagnosed multiple myeloma patients
Siyang Leng, Alexander Wei, Amer Assal, Divaya Bhutani, Gregory Baliko, Julia Gould, Ryan J Shelton, Shannon Kelly, Daniel Otap, Markus Y Mapara, Suzanne Lentzsch (abstract)
8030 - Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy
Marcella Tschautscher, S. Vincent Rajkumar, Francis Buadi, Morie A. Gertz, Martha Lacy, Angela Dispenzieri, Suzanne R. Hayman, Yi Lisa Hwa, Amie L. Fonder, Miriam A. Hobbs, Steven R. Zeldenrust, John Anthony Lust, Nelson Leung, Prashant Kapoor, Taxiarchis Kourelis, Rahma M. Warsame, Ronald S. Go, Wilson I. Gonsalves, Robert A. Kyle, Shaji Kumar (abstract)
8031 - Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE)
Michele Cavo, Shinsuke Iida, Joan Blade, Maria-Victoria Mateos, Je-Jung Lee, Mamta Garg, Vania Hungria, Meral Beksac, Ivan Spicka, Stefan Knop, Ludek Pour, Philip Campbell, Andrzej J. Jakubowiak, Jianping Wang, Susan Wroblewski, Rachel Kobos, Ming Qi, Jesus San-Miguel (abstract)
8032 - Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR
Robert Z. Orlowski, Philippe Moreau, Heinz Ludwig, Albert Oriol Rocafiguera, Wee Joo Chng, Hartmut Goldschmidt, Zhao Yang, Amy Kimball, Meletios A. Dimopoulos (abstract)
8033 - Lack of racial disparity in outcome of African American (AA) and Caucasian patients with symptomatic multiple myeloma (MM) at the Veterans Affairs (VA) hospitals
Nathanael Fillmore, Sarvari Yellapragada, Paul S. White, Chizoba Ifeorah, Mahmoud Gaballa, Gustavo Rivero, Saiju Pyarajan, Nhan Do, Mary T. Brophy, Nikhil C. Munshi (abstract)
8034 - Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma
Ben Buelow, Priya Choudry, Starlynn Clarke, Kevin Dang, Laura Davison, Shelley Force Aldred, Katherine Harris, Payal Pratap, Duy Pham, Udaya Rangaswamy, Ute Schellenberger, Nina Shah, Nathan Trinklein, Harshad Ugamraj, Arun Wiita, Wim Van Schooten (abstract)
8036 - Molecular underpinnings of clinical disparity patterns in African American (AA) versus Caucasian American (CA) multiple myeloma (MM) patients
Elizabeth M. Hill, Mary Kwok, Venkata Yellapantula, Malin Hultcrantz, Neha Korde, Sham Mailankody, Elli Papaemmanuil, Irina Maric, Dickran Garo Kazandjian, Ola Landgren (abstract)
8037 - Predictors of long-term survival in newly diagnosed multiple myeloma (NDMM) patients (pts) enrolled in the Connect MM registry
Cristina Gasparetto, Robert M. Rifkin, Howard R. Terebelo, Kathleen Toomey, Brian G. Durie, James W. Hardin, Sundar Jagannath, Lynne I. Wagner, Mohit Narang, Sikander Ailawadhi, E. Dawn Flick, Stanley Kotey, Shankar Srinivasan, Amani Kitali, Amit Agarwal, Rafat Abonour (abstract)
8038 - Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM)
Joseph Mikhael, Paul G. Richardson, Saad Zafar Usmani, Noopur S. Raje, William Bensinger, Franck Dubin, Qianying Liu, Olivier Vitse, Kenneth Carl Anderson (abstract)
8039 - Lenalidomide (LEN) pharmacokinetics (PKs) in multiple myeloma (MM) patients (pts) with various renal functions
Yanshuo Cao, MDYanshuo Cao, Eric Xueyu Chen, Lisa W Le, Olga Levina, Harminder Paul, Sumeet Kakar, Anthea Lau, Hongzhuan Chen, Christine Chen (abstract)
8040 - Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)
Sagar Lonial, Meletios A. Dimopoulos, Katja Weisel, Darrell White, Philippe Moreau, Maria-Victoria Mateos, Jesus San-Miguel, Kenneth Carl Anderson, Ofer Shpilberg, Sebastian Grosicki, Ivan Spicka, Adam Walter-Croneck, Hila Magen, Andrew Belch, Donna Ellen Reece, Meral Beksac, Suresh Shelat, Oumar Sy, Anil K. Singhal, Paul G. Richardson (abstract)
8041 - Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry
Sundar Jagannath, Robert M. Rifkin, Cristina Gasparetto, Kathleen Toomey, Brian G. Durie, James W. Hardin, Howard R. Terebelo, Lynne I. Wagner, Mohit Narang, Sikander Ailawadhi, Shankar Srinivasan, Ahmed YoussefAgha, Brian Ung, Amani Kitali, E. Dawn Flick, Amit Agarwal, Rafat Abonour (abstract)
8042 - Health-related quality of life in patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation: Results from the ALCYONE trial
Katharine Gries, John Fastenau, Ying Chen, Jianping Wang, Kai Fai Ho, Susan Wroblewski, Maria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, Ming Qi (abstract)
8043 - Real-world evidence of cardiac hospitalizations in carfilzomib- and non-carfilzomib-treated multiple myeloma patients in the United States
Joseph Mikhael, Khalid Mezzi, Karim Iskander, Kenneth Wang, Christopher Kim, Shao Zhu, Megan Braunlin, Winifred A. Werther, Ajai Chari (abstract)
8044 - The MD Anderson modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone (mCBAD) for the treatment of newly diagnosed (NDMM) and relapsed/refractory multiple myeloma (RRMM)
Samer Tabchi, Ranjit Nair, Krina K. Patel, Hans Chulhee Lee, Sheeba K. Thomas, Behrang Amini, Sairah Ahmed, Rohtesh S. Mehta, Qaiser Bashir, Muzaffar H. Qazilbash, Donna M. Weber, Robert Z. Orlowski, Raymond Alexanian, Lei Feng, Elisabet Esteve Manasanch (abstract)
8045 - Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM)
Surbhi Sidana, Nidhi Tandon, Angela Dispenzieri, Morie A. Gertz, Francis Buadi, Martha Lacy, David Dingli, Amie L. Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Wilson I. Gonsalves, Rahma M. Warsame, Taxiarchis Kourelis, Yi Lisa Hwa, Prashant Kapoor, Robert A. Kyle, Nelson Leung, Ronald S. Go, S. Vincent Rajkumar, Shaji Kumar (abstract)
8046 - Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction
R Donald Harvey, Jonathan L. Kaufman, Leonard T. Heffner, Craig C. Hofmeister, Mahdav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka (abstract)
8047 - Relationship of acquired resistance of myeloma cells to bortezomib with Lyn and Src induced inhibition of PP2A and effect of treatment with the tyrosine kinase inhibitor dasatinib
Barry Paul, Daniel Feinberg, Pasupathi Sundaramoorthy, J. Brice Weinberg, Yubin Kang (abstract)
8049 - Quality of life and cancer worry in a follow-up cohort of patients with asymptomatic monoclonal gammopathies
Michelle Ann Theobald Hildebrandt, Rashida A. Callender, Alem A. Belachew, Catherine Classen, Hans Chulhee Lee, Krina K. Patel, Tiffany Ann Richards, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Elisabet Esteve Manasanch (abstract)
8050 - Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM)
Sikander Ailawadhi, Philip L. McCarthy, Sarah A. Holstein, Gail Larkins, Weiyuan Chung, Shankar Srinivasan, Amit Agarwal, Sagar Lonial (abstract)
8051 - Association of venous thromboembolism with increased mortality in patients with multiple myeloma
Martin W. Schoen, Suhong Luo, Brian Gage, Kenneth Robert Carson, Kristen Marie Sanfilippo (abstract)
| Session | Patient and Survivor Care |
| Type | Poster Session |
| Time | Monday, June 4, 1:15 PM - 4:45 PM |
| Location | Hall A |
10025 - Hospice use among Medicare fee-for-service (FFS) or managed-care organization (MCO) enrollees with leukemia and myeloma
Adam J. Olszewski, Pamela Egan, Thomas William LeBlanc (abstract)
10043 - Utilizing a practical tablet-based modified geriatric assessment in clinic for older adults with multiple myeloma (MM)
Nitya Nathwani, Arti Hurria, Sandra E. Kurtin, Brea Lipe, Supriya Gupta Mohile, Donna Catamero, Debra Wujcik, Agnes Davis, Kristy Birchard, Carrie Tompkins Stricker, Tanya Marya Wildes (abstract)
